111 related articles for article (PubMed ID: 9816121)
41. Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF).
Akasheh M; Eastwood D; Vesole DH
Bone Marrow Transplant; 2003 Jan; 31(2):113-6. PubMed ID: 12621492
[TBL] [Abstract][Full Text] [Related]
42. Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
Janik JE; Miller LL; Kopp WC; Taub DD; Dawson H; Stevens D; Kostboth P; Curti BD; Conlon KC; Dunn BK; Donegan SE; Ullrich R; Alvord WG; Gause BL; Longo DL
Clin Immunol; 1999 Dec; 93(3):209-21. PubMed ID: 10600331
[TBL] [Abstract][Full Text] [Related]
43. Effect of granulocyte-macrophage colony-stimulating factor on growth of a xenotransplanted human ovarian cancer cell line IGROV-1 in nude mice.
Noviello E; Cosimi A; Casartelli GL; Melioli G; Taverniti G; Parodi S; Pistoia V; Venturini M; Russo P
In Vivo; 1994; 8(2):207-13. PubMed ID: 7919123
[TBL] [Abstract][Full Text] [Related]
44. Circular permutation of the granulocyte colony-stimulating factor receptor agonist domain of myelopoietin.
McWherter CA; Feng Y; Zurfluh LL; Klein BK; Baganoff MP; Polazzi JO; Hood WF; Paik K; Abegg AL; Grabbe ES; Shieh JJ; Donnelly AM; McKearn JP
Biochemistry; 1999 Apr; 38(14):4564-71. PubMed ID: 10194378
[TBL] [Abstract][Full Text] [Related]
45. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro.
Ajani JA; Blaauw AA; Spitzer G; Baker FL; Tomasovic B; Umbach G; Thielvoldt D; Zander AR; Dicke KA
Exp Hematol; 1985; 13 Suppl 16():95-100. PubMed ID: 2580731
[TBL] [Abstract][Full Text] [Related]
46. Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow.
Schwartz GN; Hakim F; Zujewski J; Szabo JM; Cepada R; Riseberg D; Warren MK; Mackall CL; Setzer A; Noone M; Cowan KH; O'Shaughnessy J; Gress RE
Br J Haematol; 1996 Mar; 92(3):537-47. PubMed ID: 8616014
[TBL] [Abstract][Full Text] [Related]
47. Influence of human granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein (PIXY321) on the hematopoietic toxicity associated with anti-viral drugs (zidovudine and didanosine) in vitro using normal human marrow cells.
Gallicchio VS; Hughes NK
Life Sci; 1995; 57(18):PL265-73. PubMed ID: 7475901
[TBL] [Abstract][Full Text] [Related]
48. [Non-Hodgkin's T cell lymphoma associated with marked eosinophilia].
Tomiyama J; Kudoh H; Suzuki F; Aoki M; Adachi Y; Enokihara H
Rinsho Ketsueki; 1993 Sep; 34(9):1011-5. PubMed ID: 8230743
[TBL] [Abstract][Full Text] [Related]
49. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study.
Vadhan-Raj S; Broxmeyer HE; Andreeff M; Bandres JC; Buescher ES; Benjamin RS; Papadopoulos NE; Burgess A; Patel S; Plager C; Hittelman WN; McAlister I; Garrison L; Williams DE
Blood; 1995 Sep; 86(6):2098-105. PubMed ID: 7662957
[TBL] [Abstract][Full Text] [Related]
50. Stimulation of pancreas and gastric carcinoma cell growth by interleukin 3 and granulocyte-macrophage colony-stimulating factor.
Dippold WG; Klingel R; Kerlin M; Schwaeble W; Meyer zum Büschenfelde KH
Gastroenterology; 1991 May; 100(5 Pt 1):1338-44. PubMed ID: 2013378
[TBL] [Abstract][Full Text] [Related]
51. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.
Miller LL; Korn EL; Stevens DS; Janik JE; Gause BL; Kopp WC; Holmlund JT; Curti BD; Sznol M; Smith JW; Urba WJ; Donegan SE; Watson TM; Longo DL
Blood; 1999 May; 93(10):3250-8. PubMed ID: 10233876
[TBL] [Abstract][Full Text] [Related]
52. Stimulation of colony formation of various human carcinoma cell lines by rhGM-CSF and rhIL-3.
Nachbaur D; Denz H; Zwierzina H; Schmalzl F; Huber H
Cancer Lett; 1990 Apr; 50(3):197-201. PubMed ID: 2157547
[TBL] [Abstract][Full Text] [Related]
53. Characterization of the microheterogeneities of PIXY321, a genetically engineered granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein expressed in yeast.
Balland A; Krasts DA; Hoch KL; Gerhart MJ; Stremler KE; Waugh SM
Eur J Biochem; 1998 Feb; 251(3):812-20. PubMed ID: 9490056
[TBL] [Abstract][Full Text] [Related]
54. The in vivo effects of PIXY321 therapy on human monocyte activity.
Hamilton RF; Vadhan-Raj S; Uthman M; Grey M; Holian A
J Leukoc Biol; 1993 Jun; 53(6):640-50. PubMed ID: 8391053
[TBL] [Abstract][Full Text] [Related]
55. Antitumor activity of bovine cartilage extract (Catrix-S) in the human tumor stem cell assay.
Durie BG; Soehnlen B; Prudden JF
J Biol Response Mod; 1985 Dec; 4(6):590-5. PubMed ID: 4087032
[TBL] [Abstract][Full Text] [Related]
56. Effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on small cell lung cancer cells.
Pedrazzoli P; Bacciocchi G; Bergamaschi G; Cazzola M; Danova M; Gibelli N; Giordano M; Lazzaro A; Locatelli F; Pavesi L
Cancer Invest; 1994; 12(3):283-8. PubMed ID: 8187006
[TBL] [Abstract][Full Text] [Related]
57. [Colony formation of solid tumors in in vitro colony assay (human tumor stem cell assay)].
Inoue K; Arakawa M; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Aiba K; Domyo M; Miyamoto H; Ikeda K
Gan To Kagaku Ryoho; 1982 Dec; 9(12):2128-32. PubMed ID: 6764097
[TBL] [Abstract][Full Text] [Related]
58. Human granulocyte-macrophage colony-stimulating factor modulates in vitro growth in only a minority of continuous human tumour cell lines. EORTC Clonogenic Assay Screening Study Group.
Eur J Cancer; 1991; 27(3):231-5. PubMed ID: 1827301
[TBL] [Abstract][Full Text] [Related]
59. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.
Hornick JL; Khawli LA; Hu P; Lynch M; Anderson PM; Epstein AL
Blood; 1997 Jun; 89(12):4437-47. PubMed ID: 9192768
[TBL] [Abstract][Full Text] [Related]
60. Clinical trials referral resource. NCI-sponsored trials of PIXY321.
Miller LL; Cheson BD; Phillips P
Oncology (Williston Park); 1993 Aug; 7(8):56, 62. PubMed ID: 8398635
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
